Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Subsidiary GenoVision Licenses DNA Extraction Method from Generation Biotech

NEW YORK, Feb. 15 (GenomeWeb News) - Qiagen said today that its wholly owned subsidiary GenoVision has licensed technology for haplotype-specific extraction of DNA from Lawrenceville, NJ-based Generation Biotech.


Under the terms of the agreement, GenoVision receives exclusive rights for the worldwide commercialization of the haplotype-specific extraction in all applications. Further financial terms were not disclosed.


The haplotype-specific extraction method physically separates DNA into its maternal and paternal alleles, enabling researchers or clinicians to determine the exact location of a mutation on both copies of the genome, Qiagen said.


Qiagen also said that the technology has been validated for use with a suite of its magnetic bead-based and automated DNA-purification technology.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.